Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American ...
2023-10-26 14:33:14 ET More on Glaukos, Sight Sciences, etc. Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support Sight Sciences: Staying Bullish After Q2 Results Beat Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Call Transcript Piper Sandler cu...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2023 fina...
2023-10-04 05:04:03 ET Summary IRIDEX Corporation is a leading provider of laser-based retinal treatments and is respected in the ophthalmic industry. IRIX stock has experienced a significant decline in value, but the primary reason for this (dilution concerns) is misguided. T...
2023-09-04 12:21:00 ET Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% co...
2023-08-31 22:51:52 ET Summary Glaukos Corporation has demonstrated its ability to unlock shareholder value with strong Q2 FY'23 numbers and growing gross profitability. Despite recent market pullback, there is still demand for Glaukos stock. The company's Q2 earnings, economi...
2023-08-02 21:30:20 ET Glaukos Corporation (GKOS) Q2 2023 Earnings Conference Call August 02, 2023, 16:30 ET Company Participants Christopher Lewis - VP, IR & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Alex Th...
2023-08-02 17:11:57 ET Glaukos press release ( NYSE: GKOS ): Q2 Non-GAAP EPS of -$0.55 beats by $0.01 . Revenue of $80.4M (+10.6% Y/Y) beats by $5.74M . For further details see: Glaukos Non-GAAP EPS of -$0.55 beats by $0.01, revenue of $80.4M beats by $5.74M
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include: ...
2023-07-17 10:46:36 ET An ophthalmic medical technology and pharmaceutical company, Glaukos ( NYSE: GKOS ) has entered into a collaboration and marketing agreement with Radius XR, whereby Glaukos will become the exclusive sales agent to market, promote, and solicit orders f...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...